Please login to the form below

Deal Watch table for April 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during April 2014.

For an indepth analysis of these deals, read 'Pharma deals during April 2014'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
GSK/ Novartis	Acquisition	Oncology portfolio including pipeline products	15,500
Biomet/ Zimmer Holdings	Acquisition	Devices - Musculoskeletal/ Orthopaedics	13,350
Novartis/ GSK	Acquisition	Vaccines portfolio, excluding influenza business	7,100
Questcor/ Mallinckrodt	Acquisition	Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions	5,600
Novartis/ Eli Lilly	Acquisition	Animal Health franchise	5,400
Ranbaxy Laboratories/ Sun Pharmaceuticals	Acquisition	Generics including Lipitor, Nexium, Diovan	3,200
Furiex/ Forest Labs	Acquisition	IBS, eluxadoline, a mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of IBD (NDA-ready)	1,460
Insight Pharmaceuticals/ Prestige Brands	Acquisition	OTC - 30 brands Women's Health and personal care products, including pregnancy testing; MONISTAT® vaginal anti-fungal	750
iPerian/ BMS	Acquisition	CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical)	725
Forma Therapeutics/ Celgene	R&D collaboration + options: to extend, license, acquire company	3.5-year drug discovery collaboration covering a broad range of protein target families	600
Andromeda Biotech/ Hyperion Therapeutics	Acquisition	DiaPep277 24-amino acid peptide derived from human heat shock protein 60 (hsp60) to treat T1DM (p3)	570
Oryzon/ Roche (pRED)	Early stage drug research pact	Oncology - LSD1 inhibitors, Orphan cancer blocker ORY-1001 (p1/2a for acute myeloid leukaemia)	521+
Iquum/ Roche	Acquisition	Molecular Diagnostics - Laboratory-in-a-tube (Liat™) System	450
AccessClosure/ Cardinal Health	Acquisition	Devices - Mynx vascular closure device	320
GSK/ Amgen	Termination	Prolia (denosumab) for osteoporosis in certain countries *	275
Sentinal Oncology/ Oncothyreon	Collaboration	Preclinical checkpoint kinase 1 (Chk1) programme	174
Aptiv Solutions/ ICON	Acquisition	CRO/ Adaptive Clinical Trials	143.5
California Stem Cell/ NeoStem	Acquisition	Stem cell immune-based therapy Melapuldencel-T, to treat metastatic melanoma (p2)	124+
New Wave Surgical/ Covidien	Acquisition	Device - D-HELP kit (to be re-named Clearify Visualization System)	100+
Agenus/ Merck & Co	Discovery collaboration/ licence	Immune checkpoint antibodies; 4-Antibody Retrocyte Display(R) platform	100
Silom Medical Company/ Actavis	Acquisition	Generics - 25 products in various dosage forms	100

All deals are worldwide unless otherwise noted.

* Amgen will assume full marketing duties in areas including the EU, Switzerland, Norway, Russia and Mexico. GSK retains rights in Australia (bone) and countries such as China, Brazil, India and South Korea for other uses.

The Deal Watch table is compiled by Medius Associates

20th May 2014